Tren is an extremely androgenic hormone, and as a result well known for promoting androgenic side effects. Hair loss and acne in men who are predisposed are both possible. Body hair growth is also possible. If you are not genetically predisposed no amount of Tren on earth with cause these issues. The androgenic side effects of Tren are truly based on genetic response. When it comes to hair loss, if you are predisposed to male pattern baldness, meaning at some point you’re going to lose your hair regardless of steroid use , Tren is one of the fastest ways to ensure you lose your hair a little sooner.
Virilization is a serious androgenic side effect of Tren. It is very difficult for a woman to use Tren without some level of virilization and makes it a steroid that’s almost never recommended for female use.
Important Note: The 5-alpha reductase enzyme does not metabolize the Trenbolone hormone. This means 5-alpha reductase inhibitors like Finasteride will not affect the androgenicity of the hormone.
On the part of trenbolone enanthate gains hematopoiesis: lymphocytopenia, eosinophilia, leukopenia, thrombocytopenia, transient neutropenia, hemolytic anemia. From the nervous system: dizziness, vertigo, drowsiness, headache, convulsions, paraesthesia, gipostezii, asthenia, insomnia, hyperactivity, aggression, anxiety , anxiety, nervousness. From the senses: hearing loss, deafness, tinnitus, taste perversion or smell, decreased visual acuity. cardio-vascular system: palpitations, arrhythmia (including ventricular tachycardia,… Read More »
Oral exemestane 25 mg/day for 2–3 years of adjuvant therapy was generally more effective than 5 years of continuous adjuvant tamoxifen in the treatment of postmenopausal women with early-stage estrogen receptor-positive/unknown receptor status breast in a large well-designed [ citation needed ] trial. Preliminary data from the open-label TEAM trial comparing exemestane with tamoxifen indicated in 2009 that exemestane 25 mg/day is also effective in the primary adjuvant treatment of early-stage breast cancer in postmenopausal women.